Cargando…
High incidence of silent venous thromboembolism before treatment in ovarian cancer
Venous thromboembolism (VTE) such as deep-vein thrombosis (DVT) and pulmonary thromboembolism (PTE) often occurs after surgery and rarely occurs even before surgery in patients with ovarian cancer. It is well known that levels of plasma D-dimer (DD) before treatment in most ovarian cancer patients a...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360447/ https://www.ncbi.nlm.nih.gov/pubmed/17895896 http://dx.doi.org/10.1038/sj.bjc.6603989 |
_version_ | 1782153051786706944 |
---|---|
author | Satoh, T Oki, A Uno, K Sakurai, M Ochi, H Okada, S Minami, R Matsumoto, K Tanaka, Y O Tsunoda, H Homma, S Yoshikawa, H |
author_facet | Satoh, T Oki, A Uno, K Sakurai, M Ochi, H Okada, S Minami, R Matsumoto, K Tanaka, Y O Tsunoda, H Homma, S Yoshikawa, H |
author_sort | Satoh, T |
collection | PubMed |
description | Venous thromboembolism (VTE) such as deep-vein thrombosis (DVT) and pulmonary thromboembolism (PTE) often occurs after surgery and rarely occurs even before surgery in patients with ovarian cancer. It is well known that levels of plasma D-dimer (DD) before treatment in most ovarian cancer patients are increased. This study therefore examined whether increased levels of DD are associated with presence of VTE before treatment of ovarian cancer. Between November 2004 and March 2007, DD levels prior to initial treatment were measured in 72 consecutive patients with presumed epithelial ovarian cancer (final diagnosis: epithelial ovarian cancer, n=60; and epithelial ovarian borderline malignancy, n=12). Venous ultrasound imaging (VUI) of the lower extremity was conducted for all patients except for two patients in whom DVT was detected by pelvic computed tomography (CT). When DVT was found, pulmonary scintigraphy was subsequently performed to ascertain presence of PTE. D-dimer levels were above the cut-off value (0.5 μg ml(−1)) in 65 of 72 patients (90.2%). Venous ultrasound imaging or CT revealed DVT in 18 of 72 patients (25.0%) and pulmonary scintigraphy found PTE in 8 patients (11.1%). All patients with VTE were asymptomatic when VTE was found. D-dimer levels were associated with incidence of VTE (0–1.4 μg ml(−1); 0 of 26 (0%), 1.5–7.4 μg ml(−1); 9 of 30 (30%) and ⩾7.5 μg ml(−1); 9 of 16 (56.3%), P for trend=0.0003). However, even if 1.5 μg ml(−1) was used as a cut-off value, this had low specificity and positive predictive value (47.2, 38.3%), though it had high sensitivity and negative predictive value (100, 100%). Therefore, ovarian cancer patients with DD level ⩾1.5 μg ml(−1) should be examined using VUI to detect silent DVT. Patients with VTE underwent preventive managements including anticoagulant therapy before initial treatment, chemotherapy or surgery, and after surgery. There was no clinical onset of postoperative VTE in all 72 patients. Measurement of DD levels and subsequent ultrasonography revealed that silent or subclinical VTE frequently occurs before surgery in ovarian cancer. The usefulness of preoperative assessment of VTE needs further confirmation in randomised controlled trials. |
format | Text |
id | pubmed-2360447 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2007 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-23604472009-09-10 High incidence of silent venous thromboembolism before treatment in ovarian cancer Satoh, T Oki, A Uno, K Sakurai, M Ochi, H Okada, S Minami, R Matsumoto, K Tanaka, Y O Tsunoda, H Homma, S Yoshikawa, H Br J Cancer Clinical Study Venous thromboembolism (VTE) such as deep-vein thrombosis (DVT) and pulmonary thromboembolism (PTE) often occurs after surgery and rarely occurs even before surgery in patients with ovarian cancer. It is well known that levels of plasma D-dimer (DD) before treatment in most ovarian cancer patients are increased. This study therefore examined whether increased levels of DD are associated with presence of VTE before treatment of ovarian cancer. Between November 2004 and March 2007, DD levels prior to initial treatment were measured in 72 consecutive patients with presumed epithelial ovarian cancer (final diagnosis: epithelial ovarian cancer, n=60; and epithelial ovarian borderline malignancy, n=12). Venous ultrasound imaging (VUI) of the lower extremity was conducted for all patients except for two patients in whom DVT was detected by pelvic computed tomography (CT). When DVT was found, pulmonary scintigraphy was subsequently performed to ascertain presence of PTE. D-dimer levels were above the cut-off value (0.5 μg ml(−1)) in 65 of 72 patients (90.2%). Venous ultrasound imaging or CT revealed DVT in 18 of 72 patients (25.0%) and pulmonary scintigraphy found PTE in 8 patients (11.1%). All patients with VTE were asymptomatic when VTE was found. D-dimer levels were associated with incidence of VTE (0–1.4 μg ml(−1); 0 of 26 (0%), 1.5–7.4 μg ml(−1); 9 of 30 (30%) and ⩾7.5 μg ml(−1); 9 of 16 (56.3%), P for trend=0.0003). However, even if 1.5 μg ml(−1) was used as a cut-off value, this had low specificity and positive predictive value (47.2, 38.3%), though it had high sensitivity and negative predictive value (100, 100%). Therefore, ovarian cancer patients with DD level ⩾1.5 μg ml(−1) should be examined using VUI to detect silent DVT. Patients with VTE underwent preventive managements including anticoagulant therapy before initial treatment, chemotherapy or surgery, and after surgery. There was no clinical onset of postoperative VTE in all 72 patients. Measurement of DD levels and subsequent ultrasonography revealed that silent or subclinical VTE frequently occurs before surgery in ovarian cancer. The usefulness of preoperative assessment of VTE needs further confirmation in randomised controlled trials. Nature Publishing Group 2007-10-22 2007-09-25 /pmc/articles/PMC2360447/ /pubmed/17895896 http://dx.doi.org/10.1038/sj.bjc.6603989 Text en Copyright © 2007 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Clinical Study Satoh, T Oki, A Uno, K Sakurai, M Ochi, H Okada, S Minami, R Matsumoto, K Tanaka, Y O Tsunoda, H Homma, S Yoshikawa, H High incidence of silent venous thromboembolism before treatment in ovarian cancer |
title | High incidence of silent venous thromboembolism before treatment in ovarian cancer |
title_full | High incidence of silent venous thromboembolism before treatment in ovarian cancer |
title_fullStr | High incidence of silent venous thromboembolism before treatment in ovarian cancer |
title_full_unstemmed | High incidence of silent venous thromboembolism before treatment in ovarian cancer |
title_short | High incidence of silent venous thromboembolism before treatment in ovarian cancer |
title_sort | high incidence of silent venous thromboembolism before treatment in ovarian cancer |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360447/ https://www.ncbi.nlm.nih.gov/pubmed/17895896 http://dx.doi.org/10.1038/sj.bjc.6603989 |
work_keys_str_mv | AT satoht highincidenceofsilentvenousthromboembolismbeforetreatmentinovariancancer AT okia highincidenceofsilentvenousthromboembolismbeforetreatmentinovariancancer AT unok highincidenceofsilentvenousthromboembolismbeforetreatmentinovariancancer AT sakuraim highincidenceofsilentvenousthromboembolismbeforetreatmentinovariancancer AT ochih highincidenceofsilentvenousthromboembolismbeforetreatmentinovariancancer AT okadas highincidenceofsilentvenousthromboembolismbeforetreatmentinovariancancer AT minamir highincidenceofsilentvenousthromboembolismbeforetreatmentinovariancancer AT matsumotok highincidenceofsilentvenousthromboembolismbeforetreatmentinovariancancer AT tanakayo highincidenceofsilentvenousthromboembolismbeforetreatmentinovariancancer AT tsunodah highincidenceofsilentvenousthromboembolismbeforetreatmentinovariancancer AT hommas highincidenceofsilentvenousthromboembolismbeforetreatmentinovariancancer AT yoshikawah highincidenceofsilentvenousthromboembolismbeforetreatmentinovariancancer |